Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct 9;14(1):23556.
doi: 10.1038/s41598-024-75293-5.

The prognostic impact of Her2 status in early triple negative breast cancer: a Turkish Oncology Group (TOG) study

Neslihan Özyurt  1 , Ali Alkan  2   3 , Burcu Gülbağcı  4 , Mustafa Seyyar  5 , Esra Aşık  6 , Mustafa Şahbazlar  7 , Mehmet Türker  8 , Oğuzcan Kınıkoğlu  9 , Tahir Yerlikaya  10 , Gülhan Dinç  11 , Ali Aytaç  12 , Ziya Kalkan  13 , Senar Ebinç  14 , İlkay Gültürk  15 , Merve Keskinkılıç  16 , Zehra Sucuoğlu İşleyen  17 , Dilek Çağlayan  18 , Alper Türkel  19 , Esra Aydın  20 , Teoman Şakalar  21 , Serhat Sekmek  22 , Nilgün Yıldırım  23 , Sinem Koçak  24 , Kerem Okutur  25 , Ahmet Özveren  26 , Bengü Dursun  27 , Sait Kitaplı  28 , Orhan Önder Eren  29 , İsmail Beypınar  30 , İlhan Hacıbekiroğlu  4 , Devrim Çabuk  5 , Elanur Karaman  6 , Ömer Acar  7 , Semra Paydaş  8 , Melek Karakurt Eryılmaz  18 , Bilgin Demir  12 , Zeynep Oruç  13 , Mesut Yılmaz  15 , Fatih Selçuk Biricik  24 , Derya Kıvrak Salim  10 , Özgür Tanrıverdi  28 , Mutlu Doğan  19
Affiliations

The prognostic impact of Her2 status in early triple negative breast cancer: a Turkish Oncology Group (TOG) study

Neslihan Özyurt et al. Sci Rep. .

Erratum in

  • Author Correction: The prognostic impact of Her2 status in early triple negative breast cancer: a Turkish Oncology Group (TOG) study.
    Özyurt N, Alkan A, Gülbağcı B, Seyyar M, Aşık E, Şahbazlar M, Türker M, Kınıkoğlu O, Yerlikaya T, Dinç G, Aytaç A, Kalkan Z, Ebinç S, Gültürk İ, Keskinkılıç M, İşleyen ZS, Çağlayan D, Türkel A, Aydın E, Şakalar T, Sekmek S, Yıldırım N, Koçak S, Okutur K, Özveren A, Dursun B, Kitaplı S, Eren OÖ, Beypınar İ, Hacıbekiroğlu İ, Çabuk D, Karaman E, Acar Ö, Paydaş S, Eryılmaz MK, Demir B, Oruç Z, Yılmaz M, Biricik FS, Salim DK, Tanrıverdi Ö, Doğan M. Özyurt N, et al. Sci Rep. 2025 Mar 18;15(1):9366. doi: 10.1038/s41598-024-80587-9. Sci Rep. 2025. PMID: 40102455 Free PMC article. No abstract available.

Abstract

The studies evaluating the impact of Her2 levels in neoadjuvant setting have conflicting data. The aim of the study was to evaluate the prognostic impact of Her2 status in early triple negative breast cancer(TNBC). In the study TNBC patients who were treated with neoadjuvant chemotherapy (NAC) and surgery were analyzed retrospectively. The primary aim of the study was to analyze the impact of Her2 status(Her2-0 and Her2-low) on pathological complete response (pCR). The secondary objectives were disease free survival (DFS) and overall survival (OS). 620 female triple negative breast cancer patients were evaluated. 427 patients (68.9%) had Her2-0 and 193(31.1%) had her2-low pathology. The pCR rates were similar between Her2-0 and Her2-low patients (33.0% vs. 27.5%, p = 0.098). Although Her2-0 group has better DFS (106 vs. 50 months, p = 0.002), in multivariate analysis it had a HR of 0.74 (p = 0.06). In addition, OS was similar (131 vs. 105 months, p = 0.13) with a HR of 0.88 (p = 0.61). In multivariate analysis; presence of LVI (HR:2.2 (95% CI 1.1-3.5) p = 0.001), Clinical stage T1/T2 (HR:0.39 (95% CI 0.2-0.6) p < 0.001) and lymph node negativity (HR:0.35 (95% CI 0.1-0.9) p = 0.03) were independent factors for OS. Although there were pathological and clinical differences, the pCR, DFS and OS were similar between Her2-0 and Her2-low TNBC patients. The importance of Her2 status of TNBC in neoadjuvant setting should be further studied.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Pathological complete response rates in Her2-0 and Her2-low groups (Her2-1 + and Her2-2+).
Fig. 2
Fig. 2
The outcomes of DFS and OS according to Her-2 status.
Fig. 3
Fig. 3
The DFS according to pCR status in Her2-0 and Her2-low groups.
See this image and copyright information in PMC

References

    1. Sung, H. et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71 (3), 209–249 (2021). - PubMed
    1. Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2020. CA Cancer J. Clin. 70 (1), 7–30 (2020). - PubMed
    1. Holliday, D. L. & Speirs, V. Choosing the right cell line for breast cancer research. Breast Cancer Res. 13 (4), 215 (2011). - PMC - PubMed
    1. Korde, L. A. et al. Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast Cancer: ASCO Guideline. J. Clin. Oncol. 39 (13), 1485–1505 (2021). - PMC - PubMed
    1. Domergue, C. et al. Impact of HER2 status on pathological response after Neoadjuvant Chemotherapy in Early Triple-negative breast Cancer. Cancers (Basel); 14(10), 2509 (2022). - PMC - PubMed

LinkOut - more resources